We are live on ! Find out more
NWBOW

Northwest Biotherapeutics, Inc.
NWBOW

Delisted

NWBOW was delisted on the 16th of December, 2016.

Back to rankings

4 hedge funds and large institutions have $455K invested in Northwest Biotherapeutics, Inc. in 2014 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

51% more capital invested

Capital invested by funds: $302K → $455K (+$153K)

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
U
UBS
Switzerland
+$584

Top Sellers

Rank Fund Capital Flow
1
SHGA
Sand Hill Global Advisors
California
-$35K
2
AIG
American International Group
New York
-$11.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Allianz Asset Management
1
Allianz Asset Management
Germany
$437K – – –
AIG
2
American International Group
New York
$17K -$11.1K -3,000 -46%
U
3
UBS
Switzerland
$1K +$584 +158 New
SHGA
4
Sand Hill Global Advisors
California
– -$35K -12,500 Closed

NWBOW Hedge Fund Activity: Q1 2014 in Review

4 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. (NWBOW) for Q1 2014, worth a combined $455K — up 51% from $302K a quarter earlier.

Fund positioning in NWBOW was balanced in Q1 2014: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was UBS, opening a new position worth an estimated $584. The largest seller was Sand Hill Global Advisors, exiting entirely with an estimated $35K sold.

  • 4 institutional investors held Northwest Biotherapeutics, Inc. (NWBOW) as of Q1 2014, unchanged from Q4 2013.
  • Funds reported $455K of Northwest Biotherapeutics, Inc. stock for Q1 2014, up 51% quarter-over-quarter.
  • 1 fund opened new Northwest Biotherapeutics, Inc. positions in Q1 2014 and 1 closed out, a net change of 0 holders.
  • The largest Northwest Biotherapeutics, Inc. buyer in Q1 2014 was UBS, an estimated $584 added.
  • The largest Northwest Biotherapeutics, Inc. seller in Q1 2014 was Sand Hill Global Advisors, an estimated $35K sold.

Based on aggregated 13F filings for Q1 2014.